Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3869 Target Snapshot

Matrix metalloproteinase-14 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,534Compounds
268Assays
6Approved Drugs
1,519.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Matrix metalloproteinase-14 shows clinical signal disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P50281. Start with breast cancer, then reuse UniProt P50281 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with breast cancer, then reuse UniProt P50281 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
breast cancer

Matrix metalloproteinase-14 shows clinical signal disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with breast cancer because it currently carries clinical signal support. Linked drugs include REBIMASTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Matrix metalloproteinase-14 as ChEMBL target CHEMBL3869, mapped to UniProt P50281. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Matrix metalloproteinase-14
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3869
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P50281
Matrix metalloproteinase-14
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Matrix metalloproteinase-14 is the right protein anchor across sources, using UniProt P50281 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why breast cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameMatrix metalloproteinase-14
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP50281
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMatrix metalloproteinase-14
UniProt AccessionP50281
Component TypeProtein
Sequence Length582 aa

Matrix metalloproteinase-14

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Matrix metalloproteinase-14, mapped to UniProt P50281. Sequence length is 582 aa.

Mapped IDP50281
Review nameMatrix metalloproteinase-14
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Matrix metalloproteinase-14 shows clinical signal disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugREBIMASTAT
Clinical signal Phase II
chronic hepatitis C virus infection
1 linked drug · 1 direct · 1 efficacy
Linked drugCTS-1027
Clinical signal Phase II
hepatitis C virus infection
1 linked drug · 1 direct · 1 efficacy
Linked drugCTS-1027
Clinical signal Phase II
lung cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugREBIMASTAT
Clinical signal Phase II
prostate adenocarcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugREBIMASTAT
Clinical signal Phase I
sarcoma
1 linked drug · 1 direct · 1 efficacy
Linked drugREBIMASTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with breast cancer because it currently carries clinical signal support. Linked drugs include REBIMASTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebreast cancer
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

6
Approved
3
Phase III
6
Phase II
Assay Mix

Activity Type Distribution

IC501,179.0
KI338.0
KD2.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL75094 9.52 IC50 0.3 Clinical
CHEMBL471537 9.49 IC50 0.32 Preclinical
CHEMBL473539 9.48 IC50 0.33 Preclinical
CHEMBL19611 9.39 IC50 0.41 Clinical
CHEMBL1801422 9.14 IC50 0.73 Preclinical
CHEMBL1092104 9.05 IC50 0.9 Preclinical
CHEMBL440498 8.96 IC50 1.1 Clinical
CHEMBL1766900 8.92 IC50 1.2 Preclinical
CHEMBL1766899 8.89 IC50 1.3 Preclinical
CHEMBL1801397 8.88 IC50 1.33 Preclinical
Distribution

pChEMBL Value Distribution

134
5.0
157
5.5
135
6.0
109
6.5
81
7.0
72
7.5
51
8.0
23
8.5
5
9.0
1
9.5
pChEMBL
Assay Landscape

Assay Landscape

268
Total Assays
820
Tested Compounds
3
Assay Types
Binding — 247 assays, 820 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 209 784 6.2
assay format 20 32 5.2
cell-based format 17 4 4.9
cell membrane format 1 0 —
ADME — 18 assays, 10 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 17 10 6.5
assay format 1 0 —
Functional — 3 assays, 56 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 3 56 4.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine